CN
Company Profile Company Culture Core Team

Home > Company > Our Mission

About Us Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management.

Singleron Biotechnologies is an innovative and rapidly growing company providing complete solutions for single-cell sequencing technologies. To improve clinical diagnosis, drug development, and health management, Singleron brings breakthrough single-cell analysis techniques to clinicans and researchers. The company was incorporated in January 2018 and currently has offices, laboratories, and manufacturing facilities in Cologne, Germany, Nanjing and Suzhou in China, and New Haven, CT, USA.

Singleron has attracted a team of experts with diverse expertise. Currently, there are about 500 full-time employees in the company. The leadership team and key employees have long-year industry experience in multinational companies, including QIAGEN, Beckton Dickinson, Roche, Illumina, Siemens, TSMC, and Novogene. The technical team has extensive and diverse hands-on experience in single-cell analysis, genomics, microfluidic systems, bioinformatics, database construction, instrument design, and clinical product development.

Singleron obtained a worldwide exclusive IP license from Yale University for its uniquely designed microfluidic single-cell processing device, and has developed the GEXSCOPE® single cell system based on this microfluidic device. The GEXSCOPE® system offers a single-cell analysis format that is highly suitable for clinical applications by addressing typical challenges in the single-cell sequencing workflow, such as difficult sample transport, complicated procedure, and high cost. Since its incorporation, Singleron has quickly developed key proprietary technologies and methods on microfluidic system design, tissue processing, single-cell barcoding and amplification, data analysis algorithms, data mining, and database construction. Singleron applied for over 100 patents and has already been granted more than 50 patents and over 50 software copyrights. GEXSCOPE® Single Cell RNA reagents and consumables, which enable RNA-seq library construction from thousands of single cells in parallel, were successfully launched in January 2019 and the Singleron Matrix instrument was launched in June 2020. The company has already worked with over 500 prominent research institutes, hospitals, and pharmaceutical companies worldwide, to promote adoption of innovative single-cell analysis technologies in clinics and drug discovery.

company culture
  • Singleron strives to provide a complete set of cutting-edge single-cell omics-solutions through rapid response to market and customer needs and rapid technological and product innovation in the developing single-cell field. Singleron accelerates breakthrough applications of single-cell technologies in clinical research and drug development.
  • Professionalism High Standards, Premium Quality
  • Accuracy Expertise, Experience, Accuracy
  • Innovation New Products, New Technologies, Pioneering, Innovative
  • Customer focused Adaptation, Dedication, Responsiveness

Core Team

core team
Management Team Scientific Advisory Board Board of Directors

  • Nan Fang
    Chair of the Board
    Chair of the Board | Founder|Chief Executive Officer| Ph.D. Immunology, University of Iowa | MBA, University of Wuerzburg | B.S., Biology, University of Science and Technology of China

    Dr. Fang has over ten years of experience in product development, commercialization, team management, and corporate strategy in world-leading biotechnology companies in Germany, US, and China. Before co-founding Singleron, Dr. Fang was Deputy General Manager at Novogene and responsible for development of novel NGS service solutions. Prior to Novogene, she was Associate Director of Global R&D at QIAGEN, Germany, founding and leading the product development team of the Universal NGS Market Program. Dr. Fang was a member of Life Sciences Business Area Management Committee at QIAGEN and directly participated in the decision-making process in the Business Area. At QIAGEN and Novogene, Dr. Fang and her team launched more than 30 products. She is inventor on over 20 patents and patent applications. Dr. Fang is also an Adjunct Professor at Anhui Medical University. Since 2018, Dr. Fang has been awarded multiple prices, including Forbes China Top 50 Women in Tech 2020; Jiangsu Province Entrepreneur of the Year 2019; one of 100 Leading Female Entrepreneurs in Nanjing; Nanjing Entrepreneurship Award; Technology Leadership of Suzhou BioBay;  Technology Leadership of Suzhou City; and Innovation and Entrepreneurship Award of Jiangsu Province.

  • Bruno Monschau
    General Manager Europe
    Managing Director Singleron Biotechnologies GmbH │ Ph.D., Max-Planck-Institute for Developmental Biology, Tübingen │ Diploma in Biochemistry, University of Tübingen.

    Dr. Monschau brings over 25 years’ experience in the Life Science and Molecular Diagnostics  industry. Prior to joining Singleron he was Site Manager of Myriad in Cologne, Germany with responsibility for product and software development, Quality Assurance (QA) and Regulatory Affairs (RA), manufacturing, purchasing and general administration. In parallel he acted as Head of QA/RA of Myriad International. Prior to Myriad, Dr. Monschau worked for 23 years in multiple positions at QIAGEN, becoming a member of QIAGEN Senior Management in 2011. In his ultimate role at Qiagen,  Dr. Monschau was the Head of Operations at two Centers of Competence (for NGS and Integrated Assays) supervising operational activities in Hilden, Germany and Barcelona, Spain. Before that, he acted as Senior Director Operations Europe responsible for manufacturing and engineering at QIAGEN’s sites in Hilden and Leipzig, Germany. Prior to this role, Dr. Monschau was Senior Director Quality Assurance, being responsible for Product QA and QC of QIAGEN sites in Germany.

  • Andreas Schmidt
    Senior Vice President
    SVP of Global Business Development │ Ph.D., University of California, Berkeley and University of Cologne │ Diploma in Biology, University of Cologne.

    Dr. Schmidt leads Singleron’s business development activities where he focuses on collaborations with clinicians and drug development companies that advance precision medicine. Dr. Schmidt is a serial entrepreneur and successful CEO in the biotechnology industry. Most recently, he was CEO of Proteona prior to its acquisition by Singleron in early 2022. Prior to Proteona, Dr. Schmidt co-founded the proteomics company AYOXXA Biosystems where he served as CEO for 7 years. Dr Schmidt serves as board member for several biotech companies and venture funds centered in Asia and Europe. He also advises public and private research and technology commercialization institutions including the European Institute of Science and Technology (EIT,) the Duke-NUS Medical School, the Singapore MIT Alliance of Research and Technology (SMART), Scaler8 and German Entrepreneurship. 

  • Jonathan Scolnick
    General Manager Singapore
    Managing Director Singleron Biotechnologies Pte. Ltd. │ Ph.D., University of California, Berkeley │ B.A., University of Texas at Austin

    Dr. Scolnick has over 20 years of experience in Research and Development in biological sciences with a focus on genomics assay development. He has worked in academia, as well as in clinical services and molecular tools-based companies such as Natera and Nugen Technologies. Most recently he was a cofounder and Chief Scientific Officer at Proteona where he was responsible for overseeing the development of both wet and dry lab tools for using single-cell biology to generate interpretable machine learning models that could predict patient response to particular drugs. With the acquisition of Proteona by Singleron Biotechnologies, Dr. Scolnick has taken on a new role as General Manager of the Singapore office where he oversees commercial activities and clinical development.

  • Jing Zhou
    Co-Founder
    Chief Scientific Officer | General Manager, Singleron U.S.| Ph.D., Mechanical Engineering, University of California, Berkeley | B.S., Modern Mechanics, University of Science and Technology of China

    Dr. Zhou, Chief Scientific Officer, is in charge of technology innovation and development, technology roadmap and IP strategy. She has over ten years experience in research and technology development in the fields of mechanical engineering, electronic technology, materials science, biotechnology and stem cells. Prior to co-founding Singleron, Dr. Zhou was Patent Agent at Dilworth IP LLC, in charge of business development in China. She was also Advisor to CEO of IsoPlexis Inc., where she was involved in the design of IsoCodeTM microfluidic chip. Dr. Zhou was Associate Research Scientist at Yale University/Yale School of Medicine and project manager of two research projects from NIH and CT Innovation as an independent PI.

  • Yifeng Gao
    Chief financial officer
    CICPA、AICPA、CIA、CMA、 Bachelor of accounting, Shanghai International Studies University

    Mr. Gao is the chief financial officer of Singleron, responsible for the overall financial work of the company. Mr. Gao received his bachelor’s degree from Shanghai International Studies University in Accounting in June 2001. After graduating, Mr. Gao worked in the audit and assurance section of Deloitte Touche Tohmatsu as senior manager. Mr. Gao held various positions in Baixing Co., Ltd., a multi-category classified platform company. During this period, he served as the chief financial officer, director and Secretary of the board of directors at the same time respectively. In addition, Mr. Gao was the chief financial officer of Frontage Holdings Group (‘Frontage’ or ‘Group’) since January 2019, responsible for the management of all aspects of the Group’s finance, tax, investment and treasury matters. Mr. Gao led the successful IPO of Frontage (01521.hk) in 2019.

  • Jue Fan
    Senior Vice President
    Senior Vice President, Bioinformatics and Data Science | Ph.D., Computational Chemistry and Biophysics, Clark University | B.S., Materials Science, University of Science and Technology of China

    Dr. Fan, Senior Vice President and Head of Bioinformatics and Data Science, is in charge of the development of bioinformatics solutions for single cell analysis and Singleron clinical single cell database. Prior to joining Singleron, Dr. Fan was CTO at IsoTex where she was in charge of development of liquid biopsy methods and products based on RNAseq and machine learning. Prior to IsoTex, Dr. Fan worked as Bioinformatics Scientist at Cellular Research Inc. and later as Manager of Bioinformatics at BD (Beckton Dickson Inc., USA)., where she developed bioinformatics analysis algorithms and pipelines for high-throughput single cell sequencing that are now core components of the single cell sequencing products from BD.

  • Xiaoyuan Zi
    Senior Vice President
    Post-doctoral Researcher, Yale University | Ph.D., Cell Biology, Second Military Medical University, Cell Biology | M.D., Clinical Medicine, Second Military Medical University

    Dr. Zi, Senior Vice President and Head of Clinical Development, is responsible for development of clinical products and applications based on single-cell analysis technologies, as well as operation of our accredited clinical laboratories. Prior to joining Singleron, Dr. Zi was Executive Director of Urology Laboratory at Shanghai Changhai Hospital, responsible for precision medicine research for prostate cancer. Dr. Zi is currently a member and secretary of the Medical Cell Biology Sub-Committee of Chinese Medical Association.

  • Long Zhang
    Senior Vice President
    VP, Marketing and Technical Support | Master of Genetics, Shanghai Jiao Tong University | MBA, University of Chicago Booth School of Business

    Mr. Zhang is in charge of marketing, product management, IvD product registration, and technical support at Singleron. He has cross-culture and cross-functional work experience in product management, strategic marketing, sales team management, research and development in multinational companies such as Roche Diagnostics, Siemens, JnJ and Qiagen. As BU Head in JnJ Medical (China), he successfully led the team to drive application of the Cellsearch for liquid biopsy. Mr. Zhang also has hands-on research experience and published peer reviewed papers on leukemia and solid tumors in top journals.

  • Yuehan Xue
    Vice President
    Internal Operation Center, Master of Crop Genetics and breeding, Hainan University

    Ms. Xue, in charge of Internal Operation Center and Human Resource& Administration, leading the service project operation, legal affairs, project application, etc. After joining Singleron (‘Company’), she rapidly organized, built and developed the team on service project operation, the Company's core business, as well as standardizing the management system and the whole operating process, which greatly accelerated the cooperation between Company and the clients.  As to her rich experience. She used to work in Annoroad, being responsible for the management of clinical laboratory and successfully completed the automatic production up-gradation of the project. Afterwards she further took charge the co-construction of the laboratory and successfully accomplished the process construction.

  • Professor Dr. Reinhard Buettner
    MD
    Professor and Chairman for Pathology, University of Cologne | Member of the German National Academy for Sciences (Leopoldina), Academia Moguntia and the Academy for Sciences NRW

    Dr. Buettner is a prominent pathologist who has pioneered the application of NGS and other breakthrough technologies in clinical applications. After completing his MD at LMU Munich, Dr. Buettner received postdoctoral training at the Gene Center Munich and MD Anderson Cancer Center, Houston (TX). Dr. Buettner is a member of the German Academy for Sciences (Leopoldina), Academia Moguntia and the Academy for Sciences NRW; the Board of Trustees of the LNS, Luxembourg; and the Board of Trustees of the German Cancer Aid. He is Founding President of the Vladimir Totovic Foundation/German Pathology.

  • Fei Sun
    MD., Ph.D.
    Dean, Medical School and Institute of Reproductive Medicine of Nantong University | Distinguished Professor of Reproductive Biology, Chief Physician in Andrology, Shanghai Jiaotong University

    Dr. Sun is a well-known expert in Reproductive Biology and Medicine. He received his PhD and MD degrees in Obstetrics & Gynecology at Fudan University. Dr. Sun has won numerous awards for his achievements in research and clinics, including: Canadian Fertility and Andrology Society Best Basic Science Research Paper (2004), Hundred-Talent Program, Chinese Academy of Sciences; Young Faculty Career Award, USTC Alumni Foundation (2007); Chief scientist of National 973 program; France Talent Innovation Laureate (2010); National Science Foundation for Distinguished Young Scholars and The leading talent of Shanghai.

  • Gary Koretzky
    MD., Ph.D.
    Vice Provost, Cornell University | Member of the National Academy of Medicine | Fellow of the American Academy of Arts and Sciences

    Dr. Koretzky is Vice Provost for Academic Integration and Professor of Medicine at Cornell University. He is an internationally renowned expert in immunology whose pioneering research contributions have improved the understanding of the development and function of immune system cells. He is a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Association for the Advancement of Science, and a member of the American Society for Clinical Investigation (1996), Association of American Physicians (1999), and the Institute of Medicine of the National Academy of Sciences (2008).  He is a past President of the American Society of Clinical Investigation (2000) and Councilor of the Association of American Physicians (2008-2012).

  • Dirk Loeffert
    Co-founder and CEO of BioMillenia
    Co-founder and CEO of BioMillenia

    Dr. Loeffert is Co-founder and CEO of BIOMILLENIA. He is a senior executive of the Life Sciences industry with more than 20 years of experience in product development and commercialization. Previously, he was Vice President of Product Development at QIAGEN, in charge of all product development activities of the Life Sciences Business Area. Dr. Loeffert has a proven track record in building high growth profitable product portfolios and has authored numerous patents. He also brings experience from having internationally managed product development teams and programs.

  • Rong Fan
    Co-Founder of Singleron
    Co-Founder of Singleron | Professor, Department of Biomedical Engineering, Yale University | Fellow of American Institute for Medical and Biological Engineering

    Dr. Fan is co-founder of Singleron Biotechnologies and an expert in using cutting-edge single-cell micro/nano-technologies to interrogate functional cellular heterogeneity and inter-cellular signaling network in human health and disease. He is also co-founder of IsoPlexis and inventor of IsoPlexis IsoCode technology, which was voted #1 of ‘2017 Top 10 Innovations’ by The Scientist and Fierce Innovation Award. Dr. Fan is recipient of numerous awards including the prestigious Packard Fellowship for Science and Engineering. Dr. Fan is also Member of Scientific Advisory Board (SAB) of Bio-Techne and IsoPlexis.

  • Nan Fang
    Chair of the Board
    Chair of the Board | Founder | Chief Executive Officer| Ph.D. Immunology, University of Iowa | MBA, University of Wuerzburg | B.S., Biology, University of Science and Technology of China

    Dr. Fang has over ten years of experience in product development, commercialization, team management, and corporate strategy in world-leading biotechnology companies in Germany, US, and China. Before co-founding Singleron, Dr. Fang was Deputy General Manager at Novogene and responsible for development of novel NGS service solutions. Prior to Novogene, she was Associate Director of Global R&D at QIAGEN, Germany, founding and leading the product development team of the Universal NGS Market Program. Dr. Fang was a member of Life Sciences Business Area Management Committee at QIAGEN and directly participated in the decision-making process in the Business Area. At QIAGEN and Novogene, Dr. Fang and her team launched more than 30 products. She is inventor on over 20 patents and patent applications. Dr. Fang is also an Adjunct Professor at Anhui Medical University. Since 2018, Dr. Fang has been awarded multiple prices, including Forbes China Top 50 Women in Tech 2020; Jiangsu Province Entrepreneur of the Year 2019; one of 100 Leading Female Entrepreneurs in Nanjing; Nanjing Entrepreneurship Award; Technology Leadership of Suzhou BioBay;  Technology Leadership of Suzhou City; and Innovation and Entrepreneurship Award of Jiangsu Province.

  • Jing Zhou
    Co-Founder
    Co-Founder | Chief Scientific Officer | General Manager, Singleron U.S. | Ph.D., Mechanical Engineering, University of California, Berkeley | B.S., Modern Mechanics, University of Science and Technology of China

    Dr. Zhou, Chief Scientific Officer, is in charge of technology innovation and development, technology roadmap and IP strategy. She has over ten years’ experience in research and technology development in the fields of mechanical engineering, electronic technology, materials science, biotechnology and stem cells. Prior to co-founding Singleron, Dr. Zhou was Patent Agent at Dilworth IP LLC, in charge of business development in China. She was also Advisor to CEO of IsoPlexis Inc., where she was involved in the design of IsoCodeTM microfluidic chip. Dr. Zhou was Associate Research Scientist at Yale University/Yale School of Medicine and project manager of two research projects from NIH and CT Innovation as an independent PI.

  • Yifeng Gao
    Chief financial officer
    CICPA、AICPA、CIA、CMA、 Bachelor of accounting, Shanghai International Studies University

    Mr. Gao is the chief financial officer of Singleron, responsible for the overall financial work of the company. Mr. Gao received his bachelor’s degree from Shanghai International Studies University in Accounting in June 2001. After graduating, Mr. Gao worked in the audit and assurance section of Deloitte Touche Tohmatsu as senior manager. Mr. Gao held various positions in Baixing Co., Ltd., a multi-category classified platform company. During this period, he served as the chief financial officer, director and Secretary of the board of directors at the same time respectively. In addition, Mr. Gao was the chief financial officer of Frontage Holdings Group (‘Frontage’ or ‘Group’) since January 2019, responsible for the management of all aspects of the Group’s finance, tax, investment and treasury matters. Mr. Gao led the successful IPO of Frontage (01521.hk) in 2019.

  • Xiaoyuan Zi
    Senior Vice President
    Senior Vice President, Clinical Development | Post-doctoral Researcher, Yale University | Ph.D., Cell Biology, Second Military Medical University, Cell Biology | M.D., Clinical Medicine, Second Military Medical University

    Dr. Zi, Senior Vice President and Head of Clinical Development, is responsible for development of clinical products and applications based on single-cell analysis technologies, as well as operation of our accredited clinical laboratories. Prior to joining Singleron, Dr. Zi was Executive Director of Urology Laboratory at Shanghai Changhai Hospital, responsible for precision medicine research for prostate cancer. Dr. Zi is currently a member and secretary of the Medical Cell Biology Sub-Committee of Chinese Medical Association.

  • Qun Zhao
    Partner, Oriza Seed

    Prior to joining Oriza Seed, Mr. Zhao had 14 years of experience in the pharmaceutical industry and had held senior management positions in a number of pharmaceutical companies. Besides VC fund for early-stage companies, Mr. Zhao also managed M&A investment funds of public company and PE fund. Mr. Zhao has been investor and board member of numerous successful companies in the healthcare industry, including Ascentage Pharma, CSTONE Pharmaceuticals (HKEX: 2616), EpimAb Biotherapeutics, Osmunda, Biocytogen, Lonwin, and BASECARE.

  • Yun Gao
    Vice President, Lilly Asia Ventures (LAV) | MBA, CEIBS | Bachelor of Medicine, Fudan University

    Yun Gao is Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Yun was most recently Investment Professional at Softbank China Venture Capital (SBCVC). Prior to that, Yun worked as Associate of Business Development and Corporate Strategy at Medtronic China and Senior Analyst at IMS Consulting Group. Yun holds an MBA degree from CEIBS and Bachelor of Medicine Degree from Fudan University.

  • Xiangyu Ouyang
    Founder and Managing Partner, Sherpa Healthcare Partners | EMBA, CKGSB | ME, Tsinghua University | BA, Wuhan University

    Prior to founding Sherpa Healthcare Partners in 2018, Mr. Ouyang joined Legend Group in 1992 and held multiple top positions including General Manager of Business Development in Legend Group including as Business Unit Head of Lenovo. In 2004, Mr. Ouyang joined Legend Capital as Managing Director and later founded the healthcare branch of Legend Capital, leading investments in numerous successful companies such as Ninestar (SSE:002180), Fortinet (NASDAQ: FTNT), Eben (acquired by Tsinghua Tongfang (SSE:600100), Lakala (300773.SZ), Lexmark ($3.9B acquisition by Ninestar), Reach Surgical, Berry Genomics (SZSE: 000710), Innovent Bio (01801.HK), Axonics(AXNX.US), Ming Te (002932.SZ), and Wuhan Asia Heart Hospital. Mr. Ouyang and his team have been ranked as Top 10 Healthcare Investor & Team in China continuously for many years. 

  • Jue Fan
    Senior Vice President
    Senior Vice President, Bioinformatics and Data Science | Ph.D., Computational Chemistry and Biophysics, Clark University | B.S., Materials Science, University of Science and Technology of China

    Dr. Fan, Senior Vice President and Head of Bioinformatics and Data Science, is in charge of the development of bioinformatics solutions for single cell analysis and Singleron clinical single cell database. Prior to joining Singleron, Dr. Fan was CTO at IsoTex where she was in charge of development of liquid biopsy methods and products based on RNAseq and machine learning. Prior to IsoTex, Dr. Fan worked as Bioinformatics Scientist at Cellular Research Inc. and later Manager of Bioinformatics at BD (Beckton Dickson Inc., USA)., where she developed bioinformatics analysis algorithms and pipelines for high-throughput single cell sequencing that are now core components of the single cell sequencing products from BD.

Social
Contact Us

E-mail:info@singleronbio.com

Phone (Germany):+49 221 16824777